Revenues Not Telling The Story For Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Simply Wall St.

Jan 02

Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) price-to-sales (or "P/S") ratio of 11.1x may look like a poor investment opportunity when you consider close to half the companies in the Medical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2600653610"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2600653610\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2600653610?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2026-01-02 18:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600653610","market":"us","top_or_hot":-1,"title":"Revenues Not Telling The Story For Establishment Labs Holdings Inc. (NASDAQ:ESTA)","media":"Simply Wall St.","content":"<div>\n<p>Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) price-to-sales (or \"P/S\") ratio of 11.1x may look like a poor investment opportunity when you consider close to half the companies in the Medical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-esta/establishment-labs-holdings/news/revenues-not-telling-the-story-for-establishment-labs-holdin\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revenues Not Telling The Story For Establishment Labs Holdings Inc. (NASDAQ:ESTA)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevenues Not Telling The Story For Establishment Labs Holdings Inc. (NASDAQ:ESTA)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-02 18:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-esta/establishment-labs-holdings/news/revenues-not-telling-the-story-for-establishment-labs-holdin><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) price-to-sales (or \"P/S\") ratio of 11.1x may look like a poor investment opportunity when you consider close to half the companies in the Medical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-esta/establishment-labs-holdings/news/revenues-not-telling-the-story-for-establishment-labs-holdin\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESTA","symbol_name":"Establishment Labs Holdings Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-esta/establishment-labs-holdings/news/revenues-not-telling-the-story-for-establishment-labs-holdin","article_id":"2600653610","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-esta/establishment-labs-holdings/news/revenues-not-telling-the-story-for-establishment-labs-holdin","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2600653610","pubTimestamp":1767350360,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Establishment Labs Holdings Inc.'s ( NASDAQ:ESTA ) price-to-sales (or \"P/S\") ratio of 11.1x may look like a poor...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ESTA":"Establishment Labs Holdings Inc.",".IXIC":"NASDAQ Composite"},"translate_title":"Establishment Labs Holdings Inc.（纳斯达克：ESTA）的收入并未说明问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESTA":1.5,".IXIC":1.5},"content_text":"Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) price-to-sales (or \"P/S\") ratio of 11.1x may look like a poor investment opportunity when you consider close to half the companies in the Medical Equipment industry in the United States have P/S ratios below 3x.   Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.    Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.  View our latest analysis for Establishment Labs Holdings NasdaqCM:ESTA Price to Sales Ratio vs Industry January 2nd 2026 What Does Establishment Labs Holdings' P/S Mean For Shareholders?  With revenue growth that's superior to most other companies of late, Establishment Labs Holdings has been doing relatively well.   It seems that many are expecting the strong revenue performance to persist, which has raised the P/S.  If not, then existing shareholders might be a little nervous about the viability of the share price.      Keen to find out how analysts think Establishment Labs Holdings' future stacks up against the industry? In that case, our free report is a great place to start.  What Are Revenue Growth Metrics Telling Us About The High P/S?   Establishment Labs Holdings' P/S ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the industry.   Retrospectively, the last year delivered an exceptional 25% gain to the company's top line.   As a result, it also grew revenue by 25% in total over the last three years.  Therefore, it's fair to say the revenue growth recently has been respectable for the company.     Looking ahead now, revenue is anticipated to climb by 28% each year during the coming three years according to the nine analysts following the company.  Meanwhile, the rest of the industry is forecast to expand by 113% per year, which is noticeably more attractive.  In light of this, it's alarming that Establishment Labs Holdings' P/S sits above the majority of other companies.  Apparently many investors in the company are way more bullish than analysts indicate and aren't willing to let go of their stock at any price.  Only the boldest would assume these prices are sustainable as this level of revenue growth is likely to weigh heavily on the share price eventually.    The Bottom Line On Establishment Labs Holdings' P/S  It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.  We've concluded that Establishment Labs Holdings currently trades on a much higher than expected P/S since its forecast growth is lower than the wider industry.  The weakness in the company's revenue estimate doesn't bode well for the elevated P/S, which could take a fall if the revenue sentiment doesn't improve.  This places shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.      Don't forget that there may be other risks. For instance, we've identified   1 warning sign for Establishment Labs Holdings  that you should be aware of.   It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E). Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechValuation is complex, but we're here to simplify it.Discover if Establishment Labs Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}